Built by Grok 4.6 High

Danaher Corporation reported third-quarter 2026 results on Wednesday, October 21, 2026. This review was prepared Monday, October 26, 2026. Quarter ended September 30, 2026. Calendar fiscal year, so the slug is 2026Q3, not the homepage calendar's announcement-quarter label. Next print is the fourth quarter, expected January 27, 2027.

DHR | Earnings Review

Reported October 21, 2026. Prepared October 26, 2026. The quarter that accelerated is not the quarter the headline is measuring. Adjusted diluted EPS was $2.11, +11.6% versus $1.89 and +9.9% versus the FMP estimate of $1.92. Sales were $6,554 million, +8.3% versus $6,053 million and $6 million under the FMP bar of $6,559.7 million. The company's own bridge tags total growth at 8.5%, of which acquisitions are 6.5 points and core growth is 3.0%. That core rate is the same as Q3 2025 (3.0%) and the same as Q2 2026 (3.0%). Core excluding respiratory did accelerate, from 4.5% to 5.5%, +100 bps. The respiratory headwind widened by the same 100 bps, to 2.5 points, so the better organic rate never reached headline core.

The beat is the margin, not the top line. Adjusted operating margin was 29.0%, +110 bps versus 27.9% and +250 bps versus the 26.5% July guide. Gross margin was only 58.5%, +30 bps versus 58.2%. Gugino called the margin beat primarily operational execution, with a modest benefit from tariff refunds received. Tariff refunds to customers were a separate 1.0% drag on reported sales and are added back to reach core. Core growth only reached the high end of the 2%–3% guide. It did not run through it.

Guidance: EPS floor up, growth algorithm unchanged, respiratory cut again. Full-year adjusted EPS is now $8.57–$8.62, from $8.45–$8.60. The midpoint moved +$0.07. The quarterly beat versus the street was +$0.19. Post-print FMP FY2026 EPS of $8.577 sits on the new floor. Q4 core excluding respiratory is 4%–5%, with respiratory still a 150 basis point headwind. Implied all-in Q4 core is about 2.5%–3.5%. That is not the mid-single-digit exit July said would produce a 3%–4% year. Cepheid respiratory was cut to $1.5 billion, and Julie Sawyer Montgomery made that the 2027 starting point for a normal season. January had called a normal year $1.8 billion.

Tone, and what the street did not get. This is Montgomery's first call as CEO. She was specific about the quarter and unwilling to sell 2027. Nine of thirteen questions were answered. The four deflections are the 2027 model: bioprocessing's rate, why ex-respiratory stays 4%–5% after a 5.5% exit, the M&A process after the misses, and Masimo's contribution. Orders are mid-teens. The guide is not. Consensus followed the guide. That is the opposite of a management-is-contrarian setup: she would not take the bull case the questions were trying to put in her mouth. Hold, because the organic rate that matters for the year is stuck, the EPS beat was not passed through, and the thing that could be better than the model is explicitly not in the model until January.

What was not available. SharePoint, OneNote, Outlook, Excel, and Teams were not available. Bloomberg and Visible Alpha are not connected. Consensus below is FMP as of October 26, 2026, not a Daloopa series. No stock price, market cap, or multiple is used.

Danaher is three segments, then core versus reported. Core strips currency and deals. Since Q2 2026 the company also shows core excluding Cepheid respiratory, because a weak flu season was hiding the base. Every growth rate below is the same quarter a year earlier. The window is eight quarters, Q4 2024 through Q3 2026. Q1 2025 company core was not returned on the Daloopa series; the call said core was flat, and that cell is left blank rather than filled with an id that does not exist.

Reported sales YoY has risen for two quarters, to +8.3%. Official half-point growth went from +5.5% to +8.5% while core stayed at 3.0% and acquisitions went from +1.5 points to +6.5 points. Gross margin had been compressing on the Q3 compare and flipped to +30 bps. Adjusted operating margin flipped from −20 bps in Q2 to +110 bps, the widest expansion in the window. Adjusted EPS growth of +11.6% is faster than Q2's +7.8% and slightly faster than last Q3's +10.5%. GAAP EPS of $1.71 is +34.6% and is not the algorithm: last year's GAAP base was the weak one.

The segments are not moving together. Life Sciences core is the clean acceleration: −1.0% a year ago to 4.5%, +550 bps, and 100 bps slower than Q2's 5.5%. Biotechnology core reaccelerated +250 bps off the Q2 air pocket to 5.0% and is still −150 bps versus last Q3's 6.5%. Reported biotech dollars were only +0.5%. Diagnostics core slowed 150 bps versus Q2's +2.0% year-over-year rate, to 0.5%, and is 300 bps below last year's +3.5%. Ex-respiratory diagnostics core, which exists only for this quarter, was 7.0%. Reported diagnostics sales of $2,882 million were +17.0%, and the acquisition contribution inside that segment was 16.5%. That is Masimo, closed June 10, not a clinical demand surge.

Recurring revenue was $5,399 million, +7.6% versus $5,017 million. Non-recurring was $1,155 million, +11.5% versus $1,036 million. Recurring was 82.4% of sales versus 82.9% a year ago. Mix did not drive the quarter. Free cash flow was $1,632 million, +19.1% versus $1,370 million. The transcript's 128% year-to-date conversion is not the Daloopa print of 135%. Use the filing.

Five completed years. FY2021 includes the Environmental and Applied Solutions business that became Veralto and is not a base. FY2022 in this table is restated continuing operations. Continuing-operations core went −10.0% to −1.5% to +2.0%. Adjusted EPS followed: −21.9%, −1.3%, +4.3%. The live year is being guided to about +10% EPS on a core rate that has not left low single digits. Nine-month 2026 sales are $18,770 million versus $17,730 million, +5.9%.

FMP, pulled October 26, not a Daloopa fundamental: Q4 revenue $7,499 million and EPS $2.50 on the earnings row ($2.483 on the analyst average). Versus Q4 2025 sales of $6,838 million and EPS of $2.23, that is about +9.7% sales and +12% EPS. FY2026 street sales of $26.275 billion are +6.9% versus $24,568 million. FY2026 street EPS of $8.58 is +10% versus $7.80 and sits inside the new guide. Faster reported growth than the +5.9% year-to-date rate is what a full quarter of Masimo produces without a faster core rate.

Adjusted EPS beat that re-widened, on a revenue print that missed by a rounding error. Pattern: mixed. EPS is a consistent beater — 11 of 12 over the last twelve quarters, the only non-beat an exact in-line in Q4 2024, and 4 of 4 over the last four. Revenue is 10 of 12 and only 2 of 4 recently. EPS-surprise magnitude had compressed from the 9%–15% cluster into +3.2%, +6.2%, +4.9%, and this quarter reopened it to +9.9% / +$0.19. The trailing-four average is still about +6.0%, because this +9.9% replaced Q3 2025's +9.9%. One quarter reopened the gap. It did not restore the old regime. Revenue surprise has deteriorated to about zero.

FMP's EPS column tracks adjusted EPS. GAAP diluted EPS from continuing operations is $1.71, $0.40 below adjusted. The street test is the adjusted number. Danaher does not guide quarterly revenue dollars or quarterly EPS. The quarterly commitments were core growth and adjusted operating margin. Core of 3.0% is the top of 2%–3%. Ex-respiratory of 5.5% is 50 bps above the 5% indication. Margin of 29.0% is 250 bps above 26.5%. The margin gap versus their own guide has widened: about +170 bps in Q1, +60 bps in Q2, +250 bps now. The Q4 margin guide just issued is 29.5%. They are not walking the new level back, and the street is not underwriting another 250 bp beat of the guide.

This quarter is highlighted.

Management does not say "versus the street." They say the quarter was better than their own expectations on growth, earnings, and cash flow. That bar is the July guide. Life Sciences core of 4.5% was above internal expectations for a third straight quarter. Bioprocessing was only modestly better, at the upper end of mid-single digits, and the full-year bioprocessing language was not raised. Respiratory was about $350 million on the call, versus the $325 million they had teed up, and they still cut the year. The $350 million is the call, not a filed tag. The beat was not fully passed through: the FY midpoint rose $0.07 against a $0.19 quarterly street beat. Seven cents is the outperformance they were willing to keep.

Last twelve quarters, 2023Q4 through 2026Q3: adjusted EPS 11 beat / 1 in-line / 0 miss. Revenue 10 beat / 2 miss, both misses inside the last three prints (Q1 2026 −0.5%, Q3 2026 −0.09%). Q4 2023 FMP revenue is unusable (the file pairs a $2,693 million actual with a $5,594 million estimate). Daloopa sales that quarter are $6,405 million. A contemporaneous Seeking Alpha score implied consensus near $6,036 million, still a beat. That quarter is in the rate, not in the eight-quarter heatmap above.

The number they actually changed is FY2026 adjusted diluted EPS. They did not restate a full-year core-growth range. They do not guide gross margin, EBITDA, revenue dollars, or free cash flow. The 2027 comment is a starting point, not a guide. FQ+1 is Q4 2026. FY+1 is FY2027.

Nine-month adjusted EPS is $2.06 + $1.94 + $2.11 = $6.11. The new year minus $6.11 is the Q4 residual: $2.46 / $2.485 / $2.51. FMP Q4 EPS of $2.483 is in line with the midpoint. The floor is a higher Q4, not a giveback: repeating $2.11 in Q4 would produce $8.22, which is $0.35 below the new low. On the filed $7.80 base, the low is +9.9% and the midpoint is +10.2%. Gugino called the year double-digit. The floor is a penny short of 10% if $7.80 is the base. Too small to call a contradiction, and large enough not to write "double digit" on the low end without rounding.

The October low ($8.57) is above the July midpoint ($8.525) and below the July high ($8.60). This is a floor raise, not a raise that clears the old range. The width collapsed from $0.15 to $0.05. EPS has been raised at every print this year, and the raise is shrinking. Respiratory has been cut at every print.

Q4 is the quarter they described, and they did not describe an all-in core rate. July's verbal exit was mid-single-digit total core because the respiratory headwind was supposed to go away. October keeps ex-respiratory at the low end of mid-single and puts 150 bps of flu drag back in. The cut versus July is the flu assumption, not a lower ex-respiratory rate. The low end of 4% is a deceleration of the 5.5% they just printed.

FMP Q4 revenue of $7,499 million is +9.7% versus $6,838 million. A 3% core outcome plus the acquisition line that adds 6.5 points this quarter lands in that neighborhood. The core bridge deducts those same 6.5 points to get to core. Masimo is in both Q3 and Q4. StatLab closed early in Q4, and no dollar was given, so 6.5 points is not a Q4 guide. Do not call $7.5 billion a beat or a miss against a 3% core guide. Q4 margin of 29.5% is +120 bps versus 28.3%. The Q3 beat included a modest tariff-refund benefit that was not identified as repeating. Gross margin is not in the outlook. Other assumptions still on the supplemental: Q4 tax rate 17% and diluted shares 708 million, down from 709 million.

FY2027 is the fight, and it is not yet a number. Montgomery's starting point is 4%–5% core excluding respiratory, because that is what the last few quarters have averaged. Q2 was 4.5% and Q3 was 5.5%, so the starting point is flat to down versus the exit rate at every point except the top of the range. FMP FY2027 EPS of $9.314 is about +8.4% versus the FY2026 guide midpoint, and FY2027 revenue of $28.292 billion is about +7.7% versus the FY2026 street revenue. A street modeling that is not an aggressive earnings ramp. It also does not require bioprocessing to leave mid-single digits. Gugino said 2027 bioprocessing growth should improve and would not adopt a high-single to low-double-digit case. Reshoring's P&L is 2028 and later.

The management-quality tell is the split. They hit and raise the EPS number. They have not been reliable on the respiratory dollar, or on the line that they would exit Q4 at mid-single-digit core with the headwinds gone. October keeps the EPS promise and softens the exit-rate promise. Caution on 2027 is consistent with that record. It is not yet "only management is contrarian."

Reported sales growth bottomed in Q1 2025 at −0.9% (−303 bps in the year-over-year rate) and has been positive since. After a grind around +4% to +5% and a soft patch in Q1 2026, it accelerated for two quarters, +188 bps then +273 bps, to +8.3%. Consolidated core went +0.5% to +3.0% to +3.0%. The second derivative of core in Q3 is zero. Acquisitions contributed 6.5 points, up from 1.5 points. On the dollar bridge, sales rose $501 million. Diagnostics rose $419 million, 84% of the increase. A company growing 8% and accelerating loses to this setup if the 8% is purchased and the organic rate is stuck.

Adjusted EPS bottomed in the same quarter (−2.1%), ran to +10.5% by Q3 2025, gave back 632 bps in Q4 2025 (+4.2%), and has since held a higher band: +9.6%, +7.8%, +11.6%. Q3 was a +386 bps reacceleration of the year-over-year rate. GAAP +34.6% is the depressed Q3 2025 base. The Q3 2025 GAAP-to-adjusted gap was $0.62. The Q3 2026 gap is $0.40. Adjusted growth is the slower, cleaner number.

What would confirm a real inflection is core, or core ex-respiratory, making a higher high without a larger acquisition contribution. Q3 did the second of those only. What can go wrong is treating Masimo's first full quarter as a run-rate, or treating mid-teens bioprocessing orders as revenue that has already been recognized. Equipment orders are building a backlog. Bioprocessing revenue is still inside a mid-single-digit year, and management did not raise that. The Q4 guide of 4%–5% ex-respiratory, with a 150 bp respiratory headwind, does not guide an acceleration of consolidated core. Implied core of roughly 2.5%–3.5% sits on the 3.0% print. The order book is ahead of the guide. The guide is not ahead of the recent core prints.

The quarter consensus is willing to underwrite is Q4 2026. It is underwriting the guide, not the order book. FMP Q4 revenue of $7,498.9 million and EPS of $2.483 sit inside a frame of about 3% core plus Masimo and a 29.5% margin. FY2026 EPS of $8.577 is the bottom of $8.57–$8.62. The street took the raise and did not move to the top. Nothing in those numbers pays for mid-teens bioprocessing orders turning into high-single-digit or low-double-digit bioprocessing growth, for a flu season above $1.5 billion, or for the autonomous-lab and NVIDIA work, which management said is not material.

Two statements are being repeated. Only one is a real gap versus the model, and it is not inside Q4. Bioprocessing orders are mid-teens and the long-term line is still high single digits, and both the CEO and the CFO refused to put that into 2027. Consensus followed the refusal. The January outlook is the catalyst that forces a choice. The AI stack is agreement, not a misunderstanding: she said it is not material, and the model treats it as not material. The respiratory cut is the other way around. They cut another $100 million with the ILI curve still under 3%. That is the guidance-accuracy behavior worth keeping. They are not raising 2027 because orders look better, and they are not hoping the flu season saves a number they no longer believe.

What would change the Q4 number before January 27: Repligen on October 27 and Revvity on November 3, if consumables orders roll over or the same mid-teens tape shows up; FluView once ILI crosses 3%; and whether the modest tariff-refund benefit was large enough to threaten the 29.5% margin. Management called it modest.

The hour was not a debate about the quarter. It was a test of whether a CEO a few weeks into the job will underwrite a faster 2027 than the 4%–5% ex-respiratory starting point. The operator capped the session at one question and one follow-up. Evie Koslosky got one question. Jack Meehan's firm is Nephron Research; the transcript's "Operon Research" is a speech-to-text error. Tally: 9 well answered, 4 deflected. The deflections are the items that set the 2027 model.

What was answered cleanly should not be folded into the deflections. She kept the operating-company structure and named the change as selling as one Danaher. The report card is accelerated profitable core growth and unambiguous share gain. The commercial rule is specific: when a solutions team calls on a customer, nobody's incentive gets worse, and she will double-pay because the share-of-wallet gain funds it. Masimo is not a medtech strategy. Respiratory at $1.5 billion has a couple hundred million of seasonal bookends and a rule for when the season counts (ILI above 3%, typically late November). The AI stack is instruments, consumables, automation, software, and scale, not material today. Reshoring is a 2028-and-later P&L event. Brownfield is modest and on the order book. The U.S. opportunity "could be a billion dollars" over several years. That billion is her phrase, not a Daloopa figure and not 2027 revenue.

What was withheld is the model.

Two live contradictions. Same-call arithmetic on the Q3 print is internally consistent. The margin and EPS beats are beats, not contradictions. A guidance revision management labels as an update is not treated as a contradiction. These two cannot both be true.

Soft tensions, not red cards. Bioprocessing dollars "a little bit north of $100 million" were pushed into 2027 in July, and October did not put that catch-up into the 4%–5% company starting point. Reconcilable as a deferred number. Not reconcilable if a model books both the $100 million and a flat 4%–5% algorithm as if both were precise. "Reagents" in the prepared remarks and "resins" in Q&A are the same mid-teens order sentence; model one print, led by upstream consumables. China up high single digits, with Diagnostics "beyond the most significant impacts" of the policy changes, is the moderation they previewed in January, not a flip. Reshoring as brownfield now and greenfield in 2028 is the same split Blair described, with the revenue year pinned later. July's "already in the revenue line" was not repeated. Her line that growth "has not consistently reflected the full potential," and that unambiguous share gain is the report card, raises the standard. It does not deny the pockets of share gain Blair claimed.

No rates call and no consumer call. Nothing was said about policy rates, Treasury yields, Danaher's own cost of debt, CPI, wages, household sentiment, or retail spending. The macro on the call is customer funding, China healthcare policy, tariffs, a flu season, and industrial capex. Versus July, the end-market tone is a bit better in biotech, academia, and China, and more specific — and later — on when reshoring hits the P&L. Do not read the flat 3.0% core print as the cycle rolling over. The ex-respiratory rate accelerated 100 bps, and the 2027 starting point is that same 4%–5% zone.

Two tariff comments, and they should not be added. Refunds to customers are a 1.0% item taken out of core. Refunds received were a modest benefit inside the margin beat. July's transcript does not contain the word tariff. This is not an inflation print, and it is not a volume tailwind.

No public competitor, supplier, or end customer was named. Danaher operating companies are not "other companies." The only outside names on the call are NVIDIA, Anthropic, Automata, Masimo, and StatLab.

Hold. The franchise underneath respiratory is in better shape than the headline: ex-respiratory core at 5.5%, Life Sciences at 4.5% after years below zero, and adjusted operating margin at 29.0% against a guide that had assumed compression. The trajectory that dominates is still the one that did not move. Headline core is 3.0% for a second quarter, the reported-sales acceleration is 6.5 points of acquisitions, and the EPS beat was kept as cushion. Management's own report card is unambiguous share gain and a faster core rate. On this call they would not underwrite either one past the rate they are already printing, and the street did not either.